Clostridium difficile--Second International Symposium (ICDS).
Tillotson
Glenn
G
Replidyne Inc, 472 Wheelers Farms Road, 3rd Floor, Milford, CT 06461, USA. GTillotson@Replidyne.com
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000737:chemistry / Q000378:metabolism; D001427:Bacterial Toxins / Q000737:chemistry / Q000378:metabolism; D002986:Clinical Trials as Topic; D016360:Clostridioides difficile / Q000187:drug effects* / Q000378:metabolism / Q000472:pathogenicity; D024881:Drug Resistance, Bacterial; D004761:Enterocolitis, Pseudomembranous / Q000382:microbiology / Q000517:prevention & control*; D004768:Enterotoxins / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D004768:Enterotoxins; C041348:tcdA protein, Clostridium difficile; C031815:toxB protein, Clostridium difficile